Hormonal
In individuals with type 2 diabetes who do not carry the haptoglobin (Hp) 2-2 phenotype, maintaining an HbA1c level below 6.5% is associated with a significantly lower risk of coronary artery disease compared to maintaining levels between 7.0% and 7.9%.
If you have type 2 diabetes and do not have the haptoglobin 2-2 genetic variant, aiming for an HbA1c below 6.5% may offer better protection against heart disease than aiming for 7.0-7.9%. This suggests that personalized glycemic targets based on genetic factors could optimize cardiovascular health.
Compared with HbA1c 7.0-7.9%, having HbA1c < 6.5% was associated with a 29% lower CAD risk among participants with the non-Hp2-2 phenotype (adjusted HR 0.71, 95% CI 0.55–0.90).
Why this rating
Large sample size (n=4,531), long follow-up (median 14.8 years), and rigorous statistical adjustment, though it is a secondary analysis of a trial.
Source
The relationship between repeated measurements of HbA1c and risk of coronary events among the common haptoglobin phenotype groups: the Action for Health in Diabetes (Look AHEAD) study
Allie S. Carew et al. · Cardiovascular Diabetology · 2024
DOI 10.1186/s12933-024-02448-z
More from this paper
- In individuals with type 2 diabetes who carry the haptoglobin (Hp) 2-2 phenotype, maintaining an HbA1c level below 6.5% does NOT significantly reduce the risk of coronary artery disease compared to levels of 7.0-7.9%.Good
- In individuals with type 2 diabetes who carry the haptoglobin (Hp) 2-2 phenotype AND have a history of cardiovascular disease, maintaining an HbA1c level of 8.0% or higher is associated with an increased risk of coronary artery disease compared to levels of 7.0-7.9%.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →